TECHNE CORP (TE1 BE) stock market data APIs
€45.0762
0(0%)
as of July 15, 2025
Try our APIs with
free plan!
TECHNE CORP Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for TE1.BE.
Prev. Close
45.0762
Open
45.0762
High
45.0762
Low
45.0762
52 wk Range
40.7326-75.6371
Market Cap
16 216 M
Dividends (Yield)
0.0054
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TECHNE CORP data using free add-ons & libraries
Get TECHNE CORP Fundamental Data
TECHNE CORP Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TECHNE CORP News
New
Here’s Headwaters Capital Management’s Investment Thesis for Bio-Techne (TECH)
Headwaters Capital Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The portfolio bounced back from the firs...
Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology
WOBURN, Mass., July 15, 2025--(BUSINESS WIRE)--Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partners...
Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection
MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling...
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy
MINNEAPOLIS, July 14, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
